Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
MorphoSys AG will publish its first nine months’ 2019 results on October 29, 2019 at 10:00pm CET
Promore Pharma AB held Extraordinary Shareholder’s Meeting on Tuesday, 22 October 2019.
HBM Healthcare Investments, Vivo Capital, BlackRock, Omega Funds, Pivotal BioVentures, and Goldman Sachs join existing investors Frazier Healthcare Partners, Bain Capital Life Sciences, OrbiMed and RA Capital Management
Companies have raised over 6x more investment thanks to grant funding
Corteva Agriscience announced a $500,000 commitment to create the Corteva Agriscience Climate Positive Challenge to catalyze a movement toward climate-positive agriculture.
Pharnext SA, a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big genomics data and artificial intelligence, announced its financial results for first-half 2019.
The deal is expected to close in the first half of 2020.
Development Programs to Focus on GI and Inflammation Therapies with Reduced, or No, Side Effects
Establishment of a debt financing plan for a maximum amount of 15 million euros, with IPF Partners
Edgewater Capital Partners announced that they have entered into an agreement to acquire Haematologic Technologies Incorporated, a leading provider of biologic products and GMP compliant assay development and testing services to the biopharmaceutical industry.